A Canadian Healthcare Innovation Agenda

2018 ◽  
Keyword(s):  
Healthcare Innovation ◽  
Canadian Healthcare

scholarly journals Canadian M.D.-Ph.D. Programs Produce Impactful Physician-Scientists: The McGill Experience

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Tianwei E. Zhou ◽  
Paul A. Savage ◽  
Mark J. Eisenberg
Keyword(s):  
Health Research ◽  
Budget Constraints ◽  
Annual Average ◽  
Protected Time ◽  
Operating Budget ◽  
Physician Scientist ◽  
Healthcare Innovation ◽  
Funding Climate ◽  
Physician Scientists ◽  
Canadian Healthcare

On June 18, 2015, the Canadian Institutes of Health Research (CIHR) announced that it would terminate funding to M.D.-Ph.D. programs due to budget constraints, against the recommendations from two advisory panels. CIHR’s M.D.-Ph.D. program grants, which amounted to an annual average of $1.8 million in the form of 14 six-year studentships, represent only 0.15% of CIHR’s $1.2 billion operating budget. As over half of M.D.-Ph.D. trainees are dependent on these studentships, this poses a threat to physician-scientist training in Canada. In response to the current volatile funding climate, we surveyed McGill University’s M.D.-Ph.D. program alumni to assess its success in producing physician-scientists. In this program, 60.0% of graduates who have completed training have become physician-scientists, the majority being retained in Canada. These individuals have attained positions with sufficiently protected time for research and had grant success and significant publications for early- to mid-career investigators. This suggests that the current M.D.-Ph.D. system is an effective way of producing competent physician-scientists. As physician-scientists have remarkably contributed to Canadian healthcare innovation despite making up a fraction of physicians and researchers, vulnerability in the M.D.-Ph.D. pipeline would invariably affect the health of Canadians.

scholarly journals Covid-19 Vaccine Acceptance, Hesitancy and Refusal among Canadian Healthcare Workers: a Multicenter Survey

2021 ◽  
Author(s):  
Stefania Dzieciolowska ◽  
Denis Hamel ◽  
Souleymane Gadio ◽  
Maude Dionne ◽  
Dominique Gagnon ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Vaccine Acceptance ◽  
Multicenter Survey ◽  
Canadian Healthcare

scholarly journals Advancing UK Regulatory Science Strategy in the Context of Global Regulation: a Stakeholder Survey

2021 ◽  
Author(s):  
Samantha Cruz Rivera ◽  
Barbara Torlinska ◽  
Eliot Marston ◽  
Alastair K. Denniston ◽  
Kathy Oliver ◽  
...  
Keyword(s):  
Pay For Performance ◽  
Regulatory Science ◽  
International Strategy ◽  
Free Text ◽  
The European Union ◽  
Accurate Definition ◽  
Definition Of ◽  
Healthcare Innovation ◽  
The Uk ◽  
Medium Enterprises

Abstract Background The UK’s transition from the European Union creates both an urgent need and key opportunity for the UK and its global collaborators to consider new approaches to the regulation of emerging technologies, underpinned by regulatory science. This survey aimed to identify the most accurate definition of regulatory science, to define strategic areas of the regulation of healthcare innovation which can be informed through regulatory science and to explore the training and infrastructure needed to advance UK and international regulatory science. Methods A survey was distributed to UK healthcare professionals, academics, patients, health technology assessment agencies, ethicists and trade associations, as well as international regulators, pharmaceutical companies and small or medium enterprises which have expertise in regulatory science and in developing or applying regulation in healthcare. Subsequently, a descriptive quantitative analyses of survey results and directed thematic analysis of free-text comments were applied. Results Priority areas for UK regulatory science identified by 145 participants included the following: flexibility: the capability of regulations to adapt to novel products and target patient outcomes; co-development: collaboration across sectors, e.g. patients, manufacturers, regulators, and educators working together to develop appropriate training for novel product deployment; responsiveness: the preparation of frameworks which enable timely innovation required by emerging events; speed: the rate at which new products can reach the market; reimbursement: developing effective tools to track and evaluate outcomes for “pay for performance” products; and education and professional development. Conclusions The UK has a time-critical opportunity to establish its national and international strategy for regulatory science leadership by harnessing broader academic input, developing strategic cross-sector collaborations, incorporating patients’ experiences and perspectives, and investing in a skilled workforce.

scholarly journals POS-321 TRANSLATING THE FINDINGS OF THE ROXADUSTAT NDD GLOBAL PHASE 3 PROGRAM INTO COST OFFSETS FROM A CANADIAN HEALTHCARE PERSPECTIVE

2021 ◽  
Vol 6 (4) ◽  
pp. S138
Author(s):  
J. Schneider ◽  
S. Davies ◽  
A. Howarth ◽  
J.J. GARCIA SANCHEZ ◽  
N. Rao ◽  
...  
Keyword(s):  
Phase 3 ◽  
Healthcare Perspective ◽  
Cost Offsets ◽  
Canadian Healthcare

The role of organisational justice, burnout and commitment in the understanding of absenteeism in the Canadian healthcare sector

2013 ◽  
Vol 27 (3) ◽  
pp. 350-367 ◽  
Author(s):  
Denis Chênevert ◽  
Genevieve Jourdain ◽  
Nina Cole ◽  
Brigitte Banville
Keyword(s):  
Healthcare Sector ◽  
Organisational Justice ◽  
Canadian Healthcare

scholarly journals Healthcare innovation

2012 ◽  
Vol 5 (4) ◽  
pp. 187-188 ◽  
Author(s):  
Susan Hamer ◽  
Thomas Plochg ◽  
Paulo Moreira
Keyword(s):  
Healthcare Innovation

scholarly journals The Accreditation Canada Program: A Complementary Tool to Promote Accountability in Canadian Healthcare

2014 ◽  
Vol 10 (SP) ◽  
pp. 150-153 ◽  
Author(s):  
Jonathan Mitchell ◽  
Wendy Nicklin ◽  
Bernadette MacDonald
Keyword(s):  
Canadian Healthcare
Sign in / Sign up

Export Citation Format

Share Document